Gene expression profiles of prostate cancer cell lines, LNCaP, PC-3 and DU 145, assessed by cDNA microarray

Kitakanto Medical Journal

Volumn 58, Issue 4, 2008, Pages 363-369

  Okamura, Keigo ^a   Koike, Hidekazu ^a   Matsui, Hiroshi ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CDNA microarray; DU 145; Gene expression profile; LNCaP; PC 3

Indexed keywords

EID: 70449643623     PISSN: 13432826     EISSN: None     Source Type: Journal    
DOI: 10.2974/kmj.58.363     Document Type: Article

References (25)

1. Johnston M: Gene chips: array of hope for understanding gene regulation. Curr Biol 8: 171-174, 1998.
2. De Saizieu A, Certa U, Warrington J, Gray C, Keck W, Mous J: Bacterial transcript imaging by hybridization of total RNA to oligonucleotidearrays. Nature Biotechnol 16: 45-48, 1998.
3. Bubendorf L, Kolmer M, Konone J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Scram P, Mooch H, Willis N, Elkahloun AG, Pret low TG, Gasser TC, Mohasco MJ, Saunter G, Kollioniemi OP: Hormone therapy failure human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758-1764, 2001.
4. Elek J, Park KH, Narayana R: Microarray-based expression profiling in prostate tumors. In Vivo 14: 173-182, 2000.
5. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, de Rijn MV, Waltham M, Pergamenschikov A, Lee JCF, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet 24: 227-235, 2000.
6. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang T, Gooden GC, Trent JM, Meltzer PS: Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58: 5009-5013, 1998.
7. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson Jr. JR, Elkahloun AG: In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 59: 5635-5661, 1999.
8. Loeffer J, Henke N, Hebart H, Schmidt D, Hagmeyer L, Schumacher U, Einsele H: Quantification of fungal DNA by using fluorescence resonance energy transfer and the Light Cycler System. J Clin Microbiol 38: 586-590, 2000.
9. Schroter M, Zolliner B, Schafer P, Laufs R, Feucht HH: Quantitative detection of hepatitis C virus RNA by Light Cycle PCR and comparison with two different PCR assays. J Clin Microbiol 39: 765-768, 2001.
10. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA: Differential cytokine and chemokine expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implication for the innate immune response.J Immunol 162: 4511-4520, 1999.
11. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics. CA-Cancer J Clin 48: 6-29, 1998.
12. Kuroishi T: International comparison of prostate cancer incidence and morbidity. Nihon Rinsho 58 (Supple.) 12-21, 2000.
13. Haas GP and Pontes JE: Management of the urological patient. In The High Risk Patient: Management of the Critically 111 Patient (E Sivak. ed.), Philadelphia, PA, Lea and Febiger, 839-856, 1995.
14. Redman GB and Pienta KJ: New treatment strategies for hormone refractory prostate cancer. Semin Urol 2: 164-169, 1995.
15. Mitchel S, Abel P, Ware M, Stamp G, Lalani EN: Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU International 85: 932-944, 2000.
16. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61: 5974-5978, 2001.
17. Dhanasekaran SM, Barrette TR, Ghoshi D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001.
18. Lue J, Duggan DJ, Chen Y, Saugageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61: 4683-4688, 2001.
19. Leung D, Abbenante G, Fairlie DP: Protease inhibitors: current status and future prospects. J Med Chem 43: 305-341, 2000.
20. Torring N, Jorgensen PE, Sorensen BS, Nexo E: Increased expression of heparin bindinng EGF (HB-EGF), amphireg-lin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.Anticancer Res 20: 91-95, 2000.
21. Vleminkx K, Vakaet L, Mareel M, Fiers W, Van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107-119, 1991.
22. Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis. Int J Cancer 72: 1-22, 1997.
23. Helenius MA, Saramaki OR, Linja MJ, Tammela TL, Visakorpi T: Amplification of Urokinase gene in prostate cancer. Cancer Res 61: 5340-5344, 2001.
24. Tansey TR and Shechter I: Structure and regulation of mammalian squalene synthase. Biochim Biophys Acta 1529: 49-62, 2000.
25. Swinnen JV and Verhoeven G: Androgens and the control of lipid metabolism in human prostate cancer cells. J Steroid Biochem Molec Biol 65: 191-198, 1998.